The latest discoveries in Neurology
A concise briefing on the most relevant research developments in your field, curated for clarity and impact.
A New Biomarker for Multiple Sclerosis Progression
A phase II trial has demonstrated promising results for nasal Foralumab, a fully human anti-CD3 monoclonal antibody, in treating progression independent of relapse activity (PIRA) in patients with nonactive secondary progressive multiple sclerosis (SPMS). The study, published in *Neurology Neuroimmunology & Neuroinflammation*, reports that the treatment was associated with a significant reduction in microglial activation, as measured by PET imaging, and showed favorable trends in clinical disability scores. This suggests a potential disease-modifying effect by targeting the innate immune system within the central nervous system.
Why it might matter to you:
This research directly intersects with the pursuit of actionable biomarkers for neurodegenerative disease. The study’s use of PET imaging to quantify microglial activation provides a concrete, correlative biomarker for treatment response, moving beyond purely clinical measures. For your work in diagnostic assays, it illustrates a pathway where a therapeutic intervention validates an imaging biomarker, which could subsequently inform the development of more accessible blood-based correlates for disease activity and treatment monitoring in MS and related conditions.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
